Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Molecular Medicine Tri-Conference 2007
18 slides from Lisata Therapeutics's conference presentation, Feb 28, 2007
Slide 1: NeoStem Business Initiatives 2007
NeoStem™ Business Initiatives 2007 Robin Smith, MD, MBA CEO and Chairman of the Board Molecular Medicine - Tri Conference February 27, 2007 - San Francisco, California
Slide 2: Forward Looking Statements
2 FORWARD LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, perfor
Slide 3: 15 Minute Agenda
3 15 Minute Agenda Collections performed at company owned centers Processing and Storage (recurring revenue) Neostem today Vision for the future Questions
Slide 4: Company Overview
4 Company Overview NeoStem: Pioneer the pre-disease collection, processing and storage of stem cells from adult donors that can be accessed for his or her own use for future medical treatment Provides a process that is safe and non-invasive Uses proprietary technology for the mobilization, processin
Slide 5: Business Model
5 Business Model NeoStem generates revenue from: Collections Storage (recurring revenue) Utilization Fee (when cells are used)
Slide 6: Market for NeoStem's Services
6 Market for NeoStem?s Services By 2010, it is estimated that 39% of the U.S. population (over 110 mm people) will be 45 years of age or older. Anticipated rapid increase in age associated diseases. Millions of Americans suffer from diseases that can be treated with their own stem cells. ?Bio-Insura
Slide 7: Stem Cell Therapeutics for Targeted Diseases
7 Stem Cell Therapeutics for Targeted Diseases *Miscellaneous Sources 53,000,000 Potential NeoStem Clients Total 204,999 diagnosed new cases per year Breast Cancer 10 million Osteoporosis 1.5 million Parkinson 200,000 Sickle Cell Anemia 20.8 million Diabetes 253,000 Spinal Cord Injury 4.7 million st
Slide 8: Adult Stem Cell Clinical Trials
8 Adult Stem Cell Clinical Trials •196 Adult Autologous Stem Cell Clinical Trials •667 Adult Stem Cell Clinical Trials
Slide 9: Adult Stem Cell Therapy in the News
9 Adult Stem Cell Therapy in the News Dr. Burt treating Lupus with adult stems cells at Northwestern Hospital.
Slide 10: Company Chronology
10 Company Chronology Signed second collection agreement with Dr. Ivan Goldsmith in Las Vegas, NV Feb ’07 Raised $2.5 million dollars through the sale of common stock and detachable warrants Jan-Feb ’07 Signed strategic alliance with UTEK to identify licensing opportunities and expand IP portfolio J
Slide 11: 2006 Go-to-Market Strategy
2006 11 “Go-to-Market” Strategy Drive General Awareness – Direct to Consumers • The benefits of storing and using Adult Stem Cells is very attractive to the media • Market as “Bio-Insurance” • High net worth & educated consumer • Family history of certain diseases • Families that have stored umbilic
Slide 12: Scientific Advisory Board
12 Scientific Advisory Board Wayne A. Marasco, M.D., Ph.D. Chairman of Scientific Advisory Board. Associate Professor- Department of Cancer and Immunology & AIDS at the Dana- Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. He will take the lead in expanding the
Slide 13: Scientific Advisory Board
13 Scientific Advisory Board Douglas W. Losordo, MD For many years a Professor of Medicine at Tufts University School of Medicine and Chief of Cardiovascular Research at St. Elizabeth’s Medical Center in Boston, Dr. Lorsordo was recently appointed Professor of Medicine at Northwestern University and
Slide 14: Scientific Advisory Board
14 Scientific Advisory Board Stephen D. Nimer, MD Dr. Nimer is Professor of Medicine and Professor of Pharmacology at Weill Medical College of Cornell University. He also serves as Chief of Hematology Service and Head of the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center
Slide 15: Advisory Board
15 Advisory Board Ron Rothenberg MD, FACEP Dr. Rothenberg is a Fellow of the American College of Emergency Physicians (FACEP) and is the founder of the California HealthSpan Institute in Encinitas, California. He was the 10th M.D. in the world to become fully board certified by the American Board of
Slide 16: Additional Company Initiatives
16 Additional Company Initiatives • Develop strategic initiatives with – Cord blood companies – Tissue banks – Pharmaceutical companies • Academic institutions for licensing opportunities and build out of collection centers • Partnerships with executive health programs, medical spas and first respon
Slide 17: Summary
17 Summary • NeoStem has the first to market advantage in the collection and storage of stem cells extracted from adults. • NeoStem represents a high growth opportunity in a large growing market. • NeoStem is well positioned with industry leaders and academic institutions. • NeoStem has an attractiv
Slide 18: Questions
18 Questions